Immunome Inc (IMNM) - Net Assets
Based on the latest financial reports, Immunome Inc (IMNM) has net assets worth $634.34 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($683.19 Million) and total liabilities ($48.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IMNM asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $634.34 Million |
| % of Total Assets | 92.85% |
| Annual Growth Rate | N/A |
| 5-Year Change | 1216.47% |
| 10-Year Change | N/A |
| Growth Volatility | 245.7 |
Immunome Inc - Net Assets Trend (2018–2025)
This chart illustrates how Immunome Inc's net assets have evolved over time, based on quarterly financial data. Also explore IMNM total assets for the complete picture of this company's asset base.
Annual Net Assets for Immunome Inc (2018–2025)
The table below shows the annual net assets of Immunome Inc from 2018 to 2025. For live valuation and market cap data, see Immunome Inc (IMNM) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $634.34 Million | +250.15% |
| 2024-12-31 | $181.16 Million | +51.12% |
| 2023-12-31 | $119.88 Million | +619.88% |
| 2022-12-31 | $16.65 Million | -65.44% |
| 2021-12-31 | $48.19 Million | +16.54% |
| 2020-12-31 | $41.34 Million | +216.04% |
| 2019-12-31 | $-35.63 Million | -41.36% |
| 2018-12-31 | $-25.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immunome Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 70205100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.00% |
| Other Components | $1.36 Billion | 214.79% |
| Total Equity | $634.34 Million | 100.00% |
Immunome Inc Competitors by Market Cap
The table below lists competitors of Immunome Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Terna Energy Societe Anonyme Commercial Technical Company
AT:TENERGY
|
$2.35 Billion |
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
$2.35 Billion |
|
China Aluminum International Engineering Corp Ltd
SHG:601068
|
$2.36 Billion |
|
Dentsply Sirona Inc
NASDAQ:XRAY
|
$2.36 Billion |
|
Ningbo Boway Alloy Material Co Ltd
SHG:601137
|
$2.35 Billion |
|
OliX PharmaceuticalsInc
KQ:226950
|
$2.35 Billion |
|
Washington Federal Inc
NASDAQ:WAFD
|
$2.35 Billion |
|
Easyhome New Retail Group Co Ltd
SHE:000785
|
$2.35 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunome Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 181,165,000 to 634,343,000, a change of 453,178,000 (250.1%).
- Net loss of 212,394,000 reduced equity.
- Other comprehensive income decreased equity by 57,000.
- Other factors increased equity by 665,629,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-212.39 Million | -33.48% |
| Other Comprehensive Income | $-57.00K | -0.01% |
| Other Changes | $665.63 Million | +104.93% |
| Total Change | $- | 250.15% |
Book Value vs Market Value Analysis
This analysis compares Immunome Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-23.07 | $22.73 | x |
| 2019-12-31 | $-6.20 | $22.73 | x |
| 2020-12-31 | $4.09 | $22.73 | x |
| 2021-12-31 | $4.18 | $22.73 | x |
| 2022-12-31 | $1.37 | $22.73 | x |
| 2023-12-31 | $6.04 | $22.73 | x |
| 2024-12-31 | $3.09 | $22.73 | x |
| 2025-12-31 | $7.26 | $22.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunome Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3059.99%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.08x
- Recent ROE (-33.48%) is above the historical average (-74.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.32 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.99 Million |
| 2020 | -41.41% | 0.00% | 0.00x | 1.08x | $-21.25 Million |
| 2021 | -51.28% | 0.00% | 0.00x | 1.20x | $-29.53 Million |
| 2022 | -221.56% | -556.75% | 0.28x | 1.44x | $-38.56 Million |
| 2023 | -89.09% | -761.92% | 0.09x | 1.24x | $-118.79 Million |
| 2024 | -161.71% | -3240.38% | 0.04x | 1.33x | $-311.08 Million |
| 2025 | -33.48% | -3059.99% | 0.01x | 1.08x | $-275.83 Million |
Industry Comparison
This section compares Immunome Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunome Inc (IMNM) | $634.34 Million | 0.00% | 0.08x | $2.35 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Immunome Inc
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine… Read more